PRISM Registry: A Novel Tool To Estimate the Prevalence of Pseudobulbar Affect Symptoms (P03.215)

CONCLUSIONS: PRISM provides novel insight into PBA symptom prevalence by prospectively evaluating a large number of patients across diagnoses and clinical settings. Follow-on studies are planned.Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus, GlaxoSmithKline, Inc., and the National Institute of Neurological Disorders and Stroke. Dr. Crumpacker has nothing to disclose. Dr. Fellus has received personal compensation for activities with Avanir Pharmaceuticals. Dr. Fellus holds stock and/or stock options in Avanir Pharmaceuticals. Dr. Kantor has received consulting fees from Avanir Pharmaceuticals, Inc. Dr. Kaye has received personal compensation for activities with Avanir Pharmaceuticals as an employee. Dr. Kaye has received research support from Avanir Pharmaceuticals.

Source: Neurology - February 14, 2013 Category: Neurology Authors: Brooks, B., Crumpacker, D., Fellus, J., Kantor, D., Kaye, R. Tags: P03 Multiple Sclerosis: Quality of Life and MS Symptoms Source Type: research